Premium
Drugmaker Dr Reddy’s Laboratories has joined the fray with biopharmaceutical company Samsung Bioepis to take over US-based Biogen’s biosimilar business, a media report said. The deal is likely to be pegged at $1 billion, The Economic Times report, citing two people close to the matter. Last week, Mint reported that Ahmedabad-based Intas Pharmaceuticals Ltd was preparing a bid for Biogen’s biosimilar business in a transaction that ......
This is a Premium article. Please subscribe or log in to read the full story!
Here's a selection of our recent premium content.
Already a member? Click here to log in.